CovidChloroV1, Main, Corpus, bibRecord, 000044

Current COVID-19 treatments: Rapid review of the literature.

Identifieur interne : 000044 ( Main/Corpus ); précédent : 000043; suivant : 000045

Current COVID-19 treatments: Rapid review of the literature.

Auteurs : Yijia Dong ; Azwa Shamsuddin ; Harry Campbell ; Evropi Theodoratou

Source :

Journal of global health [ 2047-2986 ] ; 2021.

RBID : pubmed:33959261

English descriptors

KwdEn :
- COVID-19 (therapy), Humans (MeSH), Randomized Controlled Trials as Topic (MeSH).
MESH :
- therapy : COVID-19.
- Humans, Randomized Controlled Trials as Topic.

Abstract

Background

As SARS-CoV-2 continues to spread worldwide, it has already resulted in over 110 million cases and 2.5 million deaths. Currently, there are no effective COVID-19 treatments, although numerous studies are under way. SARS-CoV-2, however, is not the first coronavirus to cause serious outbreaks. COVID-19 can be compared with previous human coronavirus diseases, such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), to better understand the development of treatments.

Methods

Databases Medline, Embase and WHO COVID-19 was systematically searched on 9 February 2021 for studies reporting on therapeutic effect of COVID-19 treatments. Clinical trials, case reports, observational studies and systematic reviews in the English language were eligible.

Results

1416 studies were identified and 40 studies were included in this review. Therapies included are: remdesivir, convalescent plasma, hydroxychloroquine, lopinavir/ ritonavir, interferon, corticosteroids, cytokine storm inhibitors and monoclonal antibodies. Remdesivir, convalescent plasma and interferon seems to provide some clinical benefits such as faster recovery time and reduced mortality, but these effects are not clinically significant. Some corticosteroids are effective in reducing mortality in severe COVID-19 patients. Hydroxychloroquine do not convey any beneficial, and therapies such as cytokine storm inhibitors and monoclonal antibodies were also not effective and require further investigation.

Conclusions

There is no single therapy effective against COVID-19. However, a combination of therapies administered at different stages of infection may provide some benefit. This conclusion is reflected in the limited effects of these treatments in previous human coronaviruses.

DOI: 10.7189/jogh.11.10003
PubMed: 33959261
PubMed Central: PMC8068411

Links to Exploration step

pubmed:33959261

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current COVID-19 treatments: Rapid review of the literature.</title>
<author><name sortKey="Dong, Yijia" sort="Dong, Yijia" uniqKey="Dong Y" first="Yijia" last="Dong">Yijia Dong</name>
<affiliation><nlm:affiliation>Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shamsuddin, Azwa" sort="Shamsuddin, Azwa" uniqKey="Shamsuddin A" first="Azwa" last="Shamsuddin">Azwa Shamsuddin</name>
<affiliation><nlm:affiliation>Centre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Campbell, Harry" sort="Campbell, Harry" uniqKey="Campbell H" first="Harry" last="Campbell">Harry Campbell</name>
<affiliation><nlm:affiliation>Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Theodoratou, Evropi" sort="Theodoratou, Evropi" uniqKey="Theodoratou E" first="Evropi" last="Theodoratou">Evropi Theodoratou</name>
<affiliation><nlm:affiliation>Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33959261</idno>
<idno type="pmid">33959261</idno>
<idno type="doi">10.7189/jogh.11.10003</idno>
<idno type="pmc">PMC8068411</idno>
<idno type="wicri:Area/Main/Corpus">000044</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000044</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Current COVID-19 treatments: Rapid review of the literature.</title>
<author><name sortKey="Dong, Yijia" sort="Dong, Yijia" uniqKey="Dong Y" first="Yijia" last="Dong">Yijia Dong</name>
<affiliation><nlm:affiliation>Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shamsuddin, Azwa" sort="Shamsuddin, Azwa" uniqKey="Shamsuddin A" first="Azwa" last="Shamsuddin">Azwa Shamsuddin</name>
<affiliation><nlm:affiliation>Centre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Campbell, Harry" sort="Campbell, Harry" uniqKey="Campbell H" first="Harry" last="Campbell">Harry Campbell</name>
<affiliation><nlm:affiliation>Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Theodoratou, Evropi" sort="Theodoratou, Evropi" uniqKey="Theodoratou E" first="Evropi" last="Theodoratou">Evropi Theodoratou</name>
<affiliation><nlm:affiliation>Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of global health</title>
<idno type="eISSN">2047-2986</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (therapy)</term>
<term>Humans (MeSH)</term>
<term>Randomized Controlled Trials as Topic (MeSH)</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>Background</b>
</p>
<p>As SARS-CoV-2 continues to spread worldwide, it has already resulted in over 110 million cases and 2.5 million deaths. Currently, there are no effective COVID-19 treatments, although numerous studies are under way. SARS-CoV-2, however, is not the first coronavirus to cause serious outbreaks. COVID-19 can be compared with previous human coronavirus diseases, such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), to better understand the development of treatments.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Methods</b>
</p>
<p>Databases Medline, Embase and WHO COVID-19 was systematically searched on 9 February 2021 for studies reporting on therapeutic effect of COVID-19 treatments. Clinical trials, case reports, observational studies and systematic reviews in the English language were eligible.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Results</b>
</p>
<p>1416 studies were identified and 40 studies were included in this review. Therapies included are: remdesivir, convalescent plasma, hydroxychloroquine, lopinavir/ ritonavir, interferon, corticosteroids, cytokine storm inhibitors and monoclonal antibodies. Remdesivir, convalescent plasma and interferon seems to provide some clinical benefits such as faster recovery time and reduced mortality, but these effects are not clinically significant. Some corticosteroids are effective in reducing mortality in severe COVID-19 patients. Hydroxychloroquine do not convey any beneficial, and therapies such as cytokine storm inhibitors and monoclonal antibodies were also not effective and require further investigation.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Conclusions</b>
</p>
<p>There is no single therapy effective against COVID-19. However, a combination of therapies administered at different stages of infection may provide some benefit. This conclusion is reflected in the limited effects of these treatments in previous human coronaviruses.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33959261</PMID>
<DateCompleted><Year>2021</Year>
<Month>05</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>05</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-2986</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>11</Volume>
<PubDate><Year>2021</Year>
<Month>Apr</Month>
<Day>24</Day>
</PubDate>
</JournalIssue>
<Title>Journal of global health</Title>
<ISOAbbreviation>J Glob Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Current COVID-19 treatments: Rapid review of the literature.</ArticleTitle>
<Pagination><MedlinePgn>10003</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.7189/jogh.11.10003</ELocationID>
<Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">As SARS-CoV-2 continues to spread worldwide, it has already resulted in over 110 million cases and 2.5 million deaths. Currently, there are no effective COVID-19 treatments, although numerous studies are under way. SARS-CoV-2, however, is not the first coronavirus to cause serious outbreaks. COVID-19 can be compared with previous human coronavirus diseases, such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), to better understand the development of treatments.</AbstractText>
<AbstractText Label="Methods" NlmCategory="UNASSIGNED">Databases Medline, Embase and WHO COVID-19 was systematically searched on 9 February 2021 for studies reporting on therapeutic effect of COVID-19 treatments. Clinical trials, case reports, observational studies and systematic reviews in the English language were eligible.</AbstractText>
<AbstractText Label="Results" NlmCategory="UNASSIGNED">1416 studies were identified and 40 studies were included in this review. Therapies included are: remdesivir, convalescent plasma, hydroxychloroquine, lopinavir/ ritonavir, interferon, corticosteroids, cytokine storm inhibitors and monoclonal antibodies. Remdesivir, convalescent plasma and interferon seems to provide some clinical benefits such as faster recovery time and reduced mortality, but these effects are not clinically significant. Some corticosteroids are effective in reducing mortality in severe COVID-19 patients. Hydroxychloroquine do not convey any beneficial, and therapies such as cytokine storm inhibitors and monoclonal antibodies were also not effective and require further investigation.</AbstractText>
<AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">There is no single therapy effective against COVID-19. However, a combination of therapies administered at different stages of infection may provide some benefit. This conclusion is reflected in the limited effects of these treatments in previous human coronaviruses.</AbstractText>
<CopyrightInformation>Copyright © 2021 by the Journal of Global Health. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dong</LastName>
<ForeName>Yijia</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shamsuddin</LastName>
<ForeName>Azwa</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Centre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Campbell</LastName>
<ForeName>Harry</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Theodoratou</LastName>
<ForeName>Evropi</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2021</Year>
<Month>04</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Scotland</Country>
<MedlineTA>J Glob Health</MedlineTA>
<NlmUniqueID>101578780</NlmUniqueID>
<ISSNLinking>2047-2978</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>5</Month>
<Day>7</Day>
<Hour>7</Hour>
<Minute>12</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>5</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33959261</ArticleId>
<ArticleId IdType="doi">10.7189/jogh.11.10003</ArticleId>
<ArticleId IdType="pii">jogh-11-10003</ArticleId>
<ArticleId IdType="pmc">PMC8068411</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Transfus Apher Sci. 2020 Oct;59(5):102875</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32694043</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Aug 15;396(10249):479-488</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32702299</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Pathol. 2020 Aug;190(8):1680-1690</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32473109</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1545-1546</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32167538</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2021 Dec 19;396(10267):1979-1993</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33220855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Aug;81(16):8692-706</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17537853</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):382-385</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32065055</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 1998 Jul 8;280(2):159-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9669790</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2021 Feb 25;384(8):693-704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32678530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 Jun;178:104786</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251767</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Sep 15;324(11):1048-1057</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32821939</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 30;395(10238):1695-1704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32401715</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2011 Feb 15;52(4):447-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21248066</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2021 Jan 9;397(10269):99-111</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33306989</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Oct;92(10):2042-2049</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32369191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2020 Dec 1;130(12):6409-6416</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32809969</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15616839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 2004 May;59(5):414-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15115870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Oct 5;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33031764</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Aug 15;396(10249):467-478</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32702298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2015 Dec 22;12:222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26695637</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Paediatr. 2020 Jun;109(6):1088-1095</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32202343</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2018 Feb 24;10(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29495250</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11585785</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2006 Jun;44(6):2063-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16757599</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2017 Jun 28;9(396):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2000 May 4;342(18):1334-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10793167</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2017 Mar 25;4(2):ofx052</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28616442</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Cent Sci. 2020 May 27;6(5):672-683</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32483554</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32470486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2017 Dec;77(18):1935-1966</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29143192</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2021 Feb;103:288-296</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33217576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2016 May;15(5):327-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26868298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Surg. 2020 Jun;78:185-193</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32305533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2010 Aug;48(8):2940-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20554810</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2020 Jun;127:104364</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32311650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1011-1019</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32291542</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 14;369:m1844</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Immunol. 2020 May;41(5):355-359</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32249063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Public Health. 2016 May-Jun;9(3):231-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27102927</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Oct 6;324(13):1330-1341</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32876694</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2020 Jun 16;222(1):38-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32348485</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2008 Sep;62(3):437-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18565970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 22;395(10224):e39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32035510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Infect. 2004 Jul;10(7):676-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15214887</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 19;383(21):2030-2040</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33031652</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2016 Jan;22(1):49-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26692185</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2021 Jan 20;372:n84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33472855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2019 Dec 12;381(24):2293-2303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31774950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Cell Biol. 2020 May 18;12(4):322-325</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32236562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Immunopharmacol. 2020 Nov;88:106903</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32862111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Jun;89(11):6117-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25787284</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Jun 12;368(6496):1274-1278</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32404477</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2021 Feb;103:439-446</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33285283</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Rheumatol. 2020 Jul;2(7):e393-e400</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32835245</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2021 Jan 21;384(3):238-251</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33332778</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jun;92(6):556-563</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32104907</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19506054</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Apr 25;395(10233):1321-1322</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32277876</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2016 Dec;71(12):3340-3350</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27585965</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2006 Apr 20;354(16):1671-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16625008</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Jul 30;370:m2980</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32732190</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2021 Jan 1;181(1):32-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33080017</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med Sci. 2020 Aug;360(2):120-128</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32709280</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Aug;81(2):318-356</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32333918</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Oct 22;371:m3939</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33093056</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2020 May 14;55(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Aug 4;324(5):460-470</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32492084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 May 12;323(18):1824-1836</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Jun 26;368(6498):1422-1424</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32461212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2018 Feb 06;19(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29415501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Aug 7;369(6504):643-650</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32540902</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2021 Jan 13;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33440088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1813-1826</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32445440</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2009 Sep;15(9):1377-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19788804</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Immunol. 2020 Jun 5;5(48):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32503877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2021 Feb;9(2):196-206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33189161</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2021 Jan 7;384(1):20-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33332779</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Microbiol. 2017 Jan;25(1):35-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27743750</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Postgrad Med J. 2004 Jul;80(945):373-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15254300</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Sep;585(7824):273-276</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32516797</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Microbiol. 2001;55:255-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11544356</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2013 Nov 15;208(10):1634-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23922367</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheum Dis Clin North Am. 2016 Feb;42(1):15-31, vii</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26611548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2020 Aug 20;64(9):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32661006</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000044 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000044 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:33959261
   |texte=   Current COVID-19 treatments: Rapid review of the literature.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:33959261" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Current COVID-19 treatments: Rapid review of the literature.

Current COVID-19 treatments: Rapid review of the literature.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki